Adverse Outcome Pathways
Adverse outcome pathways use existing data to organize information about biological interactions and toxicity mechanisms into models that describe how chemical exposures might cause toxic effects.
Development of AOPs is an international effort that NICEATM supports through the following activities.
|Adverse Outcome Pathways: From Research to Regulation||Over 100 attendees at this 2014 workshop explored how scientific progress in adverse outcome pathway concepts can improve regulatory assessment of chemical toxicity. The workshop was co-organized by NICEATM and Physicians Committee for Responsible Medicine.||Kleinstreuer et al. 2016. Adverse Outcome Pathways: From Research to Regulation. Scientific workshop report. Reg Toxicol Pharmacol 76:39-50|
|AOP for skin sensitization caused by chemicals that covalently bind to skin proteins||NICEATM contributed to this AOP issued by the Organisation for Economic Co-operation and Development.||OECD Guidance Document 168, “The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins,” available on the OECD website|
|AOP for disruption of embryonic vascular development||NICEATM contributed to this AOP for exposures leading to adverse prenatal outcomes.||Knudsen and Kleinstreuer. 2011. Disruption of embryonic vascular disruption in predictive toxicology. Birth Defects Res C Embryo Today 93(4):312-23|
|Data resources to support AOP development||Ontological mappings for assay endpoints are included in the NICEATM Integrated Chemical Environment resource to support development of AOP-based integrated approaches to testing and assessment.||(none)|